Drug intelligence / Profile preview

Testosterone Nasal Gel

Development stage: Phase 2
Lead developer: First Generation Capital
Modality: Small Molecules
Administration: Intranasal

Overview

Testosterone Nasal Gel (TBS-2) is a pharmaceutical formulation of testosterone delivered intranasally. It is being developed for the treatment of female sexual dysfunction (FSD), including female orgasmic disorder and female sexual interest/arousal disorder (FSIAD). As an intranasal testosterone, its mechanism of action involves supplementing testosterone levels, which then acts on androgen receptors to potentially improve sexual responsiveness and desire in women.

Other names: intranasal testosterone

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Testosterone Nasal Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Testosterone Nasal Gel.

Explore the full profile